ReachMD CME

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.=

CME credits: 1.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/ A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems. =

CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.=

CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It's not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice.For more information please visit the Heart Failure Congress 2026 website.=

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-reframing-first-line-and-subsequent-care-in-advanced-urothelial-carcinoma-clinical-implications-of-the-updated-nccn-guidelines/54396/ This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC.=

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-her2-in-solid-tumors-from-pathology-to-personalized-treatment-plans/54582/ Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events.=

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/before-the-scalpel-identifying-candidates-for-perioperative-immunotherapy/57086/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/choosing-the-path-forward-a-real-world-dialogue-on-perioperative-immunotherapy/57089/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/partnering-through-treatment-preparing-for-immunotherapy-in-the-perioperative-setting/57090/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-evidence-into-action-applying-perioperative-data-to-real-world-practice/57091/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/all-hands-on-deck-multidisciplinary-coordination-for-smarter-perioperative-care/57093/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.25 Valid until: 26-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/Making-the-Right-Moves-in-Metastatic-CSPC-Intensification-Imaging-and-Impact/56687/ Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regimens that improve overall survival and other clinically meaningful outcomes. The faculty examine how disease burden, metastatic pattern, genomic features, comorbidities, and patient fitness inform selection of doublet versus triplet therapy. They also highlight multidisciplinary approaches to managing treatment-related adverse events and preserving quality of life in patients receiving intensified treatment.=

CME credits: 0.25 Valid until: 21-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-the-latest-kdigo-guidelines-into-practice-iv-iron-therapy-in-patients-with-nondialysis-dependent-ckd/54631/ Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only screening insufficient. Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD highlight the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD, along with the need for proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes. =

CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-in-focus-a-case-based-approach-to-diagnosis-and-assessment/49150/ In this case-based discussion, Drs. Dolinger and Rubin examine the diagnostic approach to patients presenting with signs and symptoms suggestive of inflammatory bowel disease (IBD). The conversation explores key steps in the initial evaluation, appropriate laboratory testing, the role of colonoscopy versus additional noninvasive work-up, and how imaging modalities such as intestinal ultrasound contribute to disease characterization. The faculty also address methods to assess disease severity and activity, incorporating clinical indices, endoscopic findings, and risk stratification.=

CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/movements-with-meaning-reading-the-pattern-not-the-label/54715/ This Podcast Plus discussion examines how to distinguish tardive dyskinesia (TD) from other movement disorders using clinical features, medication timing, and response patterns. Key characteristics of TD, including irregular orofacial movements, are compared with drug-induced parkinsonism and akathisia. The discussion highlights the delayed onset of TD following dopamine receptor-blocking agents and compares timing across movement syndromes. It also emphasizes why TD should not be grouped with other extrapyramidal symptoms, as it may be missed, masked, or coexist with other conditions, affecting treatment decisions.=

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-movements-steal-lives-td-burden-stigma-and-the-therapeutic-alliance/56641/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/subtle-vs-syndromic-distinguishing-td-from-other-dimds-in-the-neuro-clinic/56642/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-15-minute-med-check-making-aims-and-td-screening-routine-in-psychiatry/56643/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-equity-disparities-and-access-to-td-diagnosis-and-care/56644/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/not-all-vmat2s-are-the-same-understanding-the-pkpd-differences/56645/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-eps-to-personalized-td-treatment-matching-vmat2-moa-to-the-patient/56646/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/treating-the-complex-patient-td-management-in-older-adults-and-medically-fragile-populations/56647/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/shared-decisions-real-patients-patient-centered-td-and-antipsychotic-strategies/56648/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 0.25 Valid until: 11-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-across-the-spectrum-of-her2-expression-in-hr-metastatic-breast-cancers-practice-changes-to-improve-care/32203/ This discussion, led by an expert in quality improvement (QI) implementation, will showcase the outcomes and experiences of clinicians participating in a QI initiative designed to improve the diagnosis, identification, and treatment of patients with HER2-expressing metastatic breast cancer (MBC). Panelists will share their successes and on-going challenges in the identification of patients with HER2-low or HER2-ultralow MBC and integration of HER2-directed ADCs among the healthcare team. Panelists will also highlight key findings, lessons learned, and improvements made as a result of the initiative. The discussion will focus on reporting and communication changes that promoted more visible and actionable information in support of interprofessional care coordination and treatment decision-making.=

CME credits: 0.25 Valid until: 11-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-trop2-targeted-adcs-in-tnbc-and-hr-mbc/54128/ Dr. Adam Brufsky reviews the clinical role of TROP2-targeted antibody–drug conjugates (ADCs) in hormone receptor–positive (HR+) and metastatic triple-negative breast cancer (TNBC), emphasizing areas of unmet need following CDK4/6 inhibitor progression. He outlines the mechanisms of ADCs and summarizes key phase 3 trial data, highlighting improvements in progression-free survival and, in some cases, overall survival compared with standard chemotherapy. The evolving role of TROP2 ADCs in both later-line and first-line settings is emphasized, underscoring the expanding use of TROP2-directed therapies. Dr. Brufsky also highlights current NCCN guideline recommendations and addresses considerations such as patient selection, sequencing, and trial limitations. =

CME credits: 0.25 Valid until: 08-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/ This interview-style activity brings together a physician and nurse to explore the scientific rationale and clinical evidence behind subcutaneous (SC) immune checkpoint inhibitors (ICIs) in solid tumors. Through discussion of key clinical trials, they highlight pharmacokinetic equivalence, efficacy, and safety data compared with intravenous delivery. The conversation also offers practical insights for integrating SC ICIs into clinical workflows—including patient selection, administration techniques, and management of immune-related adverse events—while considering potential benefits for patient experience, nursing practice, and healthcare resource use.=

CME credits: 0.50 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/ Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention.=

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/sequencing-systemic-and-local-therapy-in-her2-overexpressing-metastatic-nsclc/56520/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 0.75 Valid until: 06-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/secondary-stroke-prevention-emerging-role-factor-xi-inhibition/50969/ Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn't have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You'll break down the science behind FXI, review key clinical trial data, and examine where these therapies may fit in secondary stroke prevention. Through real-world scenarios, discover how FXI inhibitors could help address residual stroke risk without the same bleeding concerns that limit current options.=

CME credits: 0.25 Valid until: 06-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/dka-real-world-evidence-cases/50981/ Recently, an international panel of experts developed objective practical recommendations on how continuous ketone monitoring could improve diabetes care. Even more recently, new data was presented on the prevalence, risk, burden, and management of DKA. Join worldwide experts as they discuss the practical application of all of these advances into your current practice.=

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-of-ibd-the-war-within/56889/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-inflammation-in-ibd-localized-vs-systemic-strategies/56890/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-biology-environmental-and-lifestyle-influences-in-ibd/56891/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-microbiomes-role-in-ibd-management/56892/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/genetic-susceptibility-in-ibd-from-risk-genes-to-clinical-impact/56893/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.